It also addresses the blood-clotting risks of erythropoiesis-stimulating agents
and recommends discontinuing their use beyond 6-8 weeks if the patient has not responded to therapy.
Initial penetration of biosimilar erythropoiesis-stimulating agents
in the U.
SAN FRANCISCO -- Cancer patients on erythropoiesis-stimulating agents
are 17% more likely to die of any cause while in clinical trials and 6% less likely to be alive at the longest available follow-up, researchers reported at the annual meeting of the American Society of Hematology.
To treat anemia successfully in veterans, physicians administer erythropoiesis-stimulating agents
Articles involving erythropoiesis-stimulating agents
(ESAs) were reviewed in order to search for any link between pharmaceutical industry funding and basic scientific research results.
(ESAs) stimulate bone marrow to increase the production of red blood cells, lowering the need for blood transfusions during chemotherapy in cancer patients.
The blockbuster drugs are part of a class called erythropoiesis-stimulating agents
(ESAs), which are approved for treating patients with kidney disease and cancer.
WASHINGTON -- Limiting the use of erythropoiesis-stimulating agents
in patients with chemotherapy induced anemia would greatly increase demand for blood products and impose considerable pressure on the available U.
These drugs are called erythropoiesis-stimulating agents
are contraindicated for a hemoglobin of greater than 10 and carry significant risk.